XO

$IMMX Based on short-term price targets offered by four analysts, the average price target for Immix Biopharma, Inc. comes to $18.25. The forecasts range from a low of $15.00 to a high of $23.00.

As of April 13, 2026, the 1-year analyst price target for Arrive AI $ARAI $12.00 Do ur dd in buying any stock

$ARAI was $40 stock at $1.32 looks like on the move surging due to securing its tenth US patent for its autonomous , secure drone/robot delivery technology. Do your dd in buying any stock

$IMMX Analyst Target: Analysts have set a high price target of $23.00, with an average target of $17.56 - $18.25, suggesting a potential significant upside from current levels.

$IMMX high was $11.62 need to get to that 52 week high and we break to next level my opinion

$IMMX looks like they keep moving target price. Based on short-term price targets offered by four analysts, the average price target for Immix Biopharma, Inc. comes to $18.25. The forecasts range from a low of $15.00 to a high of $23.00. The average price target

$TE The average 12-month analyst price target for T1 Energy Inc. (TE) is approximately $10.00to $10.50, representing a potential upside of over 120% from its current price of ~$4.48.

$IMMX Analyst Upgrades: Mizuho raised its price target for IMMX to $15.00, while H.C. Wainwright also maintained a $15.00 target, expressing confidence in the company's cash position.

President Trump on Iran. From 1980 to now.

$IMMX on the move !! Longterm stock looks like Good things happening with this undervalued Gem in my opinion !

A commitment to break the status quo in serious disease continues to shape our work at Immix Biopharma. In rare diseases like AL Amyloidosis, there remains a clear need for new treatment approaches. NXC-201, an investigational CAR-T therapy, is being studied in the NEXICART-2 clinical trial for patients with relapsed/refractory AL Amyloidosis, with ongoing evaluation of its safety and efficacy. #IMMX #Celltherapy #Biotech #ALAmyloidosis $IMMX

💥 $IMMX — The Undiscovered Biotech Comeback Immix Biopharma ($IMMX) is quietly positioning itself as one of the most overlooked plays in next-gen CAR-T therapy. 🔬 Lead candidate NXC-201 targets AL Amyloidosis, a deadly and underserved disease — with potential first-in-class, one-time cell therapy status. A successful trial here could unlock a multi-billion orphan market with minimal competition. 💡 Immix’s “no-maintenance” CAR-T design and N-GENIUS™ platform aim to deliver stronger efficacy with fewer side effects — a major edge vs traditional CAR-T. 📈 Market cap sits near $120M, while peers in late-stage trials trade 5-10x higher. With early-stage validation and growing clinical data, upside potential remains massive. Disclaimer: shorturl.at/esara #IMMX #Biotech #Stocks #Momentum #CAR-T #GrowthStocks

AL Amyloidosis is caused by abnormal plasma cells flooding the body with toxic proteins called light chains. These light chains accumulate in the heart, kidneys, and liver, silently causing organ damage before most patients are ever diagnosed. For the ~38,500 Americans living with the relapsed/refractory form, the stakes couldn't be higher. The median time from first symptom to diagnosis is often years, which matters enormously when organs are already under attack. At Immix Biopharma, raising awareness isn't just a mission statement. It's the foundation of everything we do, because earlier diagnosis means more patients may benefit from potentially transformative therapies. Learn more about AL Amyloidosis → immixbio.com #ALAmyloidosis #RareDisease #PatientAwareness #Biopharma #CellTherapy #IMMX $IMMX

$TE T1 Energy is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 31, 2026, T1 Energy Inc. (NYSE:TE) maintained its 2026 production and sales guidance of 3.1–4.2 GW. finance.yahoo.com/sectors/energy…

$PFE Prediction: In 5 Years, You'll Wish You Bought Pfizer Stock Today The healthcare stock looks ridiculously undervalued. By David Jagielski, CPA – Apr 7, 2026 at 10:00AM EST

537,000 gallons of liquid hydrogen. 196,000 gallons of liquid oxygen. 60,000 solar cells. All for this view. Thank you, Artemis II astronauts. Image Credit: @NASA

$PFE this is longterm stock it’s a hold my opinion it doe sent belong at these levels and it has dividend. 5-10 years you will be pleased

$IMMX Immix Biopharma (IMMX) has a consensus "Buy" or "Strong Buy" rating from analysts, with 12-month price targets ranging from $15 to $23, representing a potential upside of over 100% from recent prices. The bullish outlook is driven by its CAR-T candidate NXC-201,

$TE The average 12-month analyst price target for T1 Energy Inc. (TE) is approximately $10.00to $10.50, representing a potential upside of over 120% from its current price of ~$4.48.

$IMMX immixbio.com/at-ash-2025-or…